Lyra Therapeutics, Inc. 8-K

What Happened
Lyra Therapeutics, Inc. announced in an 8-K (Item 1.02) that it entered into a Termination of Sublease with RVAC Medicines (US), Inc. to end its sublease for approximately 23,704 rentable square feet at 880 Winter Street, Waltham, Massachusetts. The sublease (originally dated December 21, 2023) was terminated effective March 31, 2026, and Lyra must surrender the premises no later than May 31, 2026.

Key Details

• Sublease space: ~23,704 rentable sq ft at 880 Winter St., Waltham, MA.
• Termination effective date: March 31, 2026; surrender deadline: May 31, 2026.
• Cash payment: Lyra agreed to a $2,100,000 termination payment.
• Security deposit: Lyra’s $600,501.32 letter of credit will be released and returned after surrender; Lyra’s rent obligations ended as of January 31, 2026.

Why It Matters
This filing documents the formal end of a material lease commitment. For investors, the key takeaways are a one-time cash outflow of $2.1M to exit the sublease and a subsequent recovery of about $600.5K of collateral once surrender obligations are met. The termination removes ongoing rent obligations associated with the Waltham space (rent obligations already ended Jan 31, 2026), which could lower future occupancy expense and obligations on Lyra’s balance sheet.